GSA Capital Partners LLP Acquires Shares of 46,989 Biodesix, Inc. $BDSX

GSA Capital Partners LLP bought a new position in shares of Biodesix, Inc. (NASDAQ:BDSX) during the second quarter, HoldingsChannel.com reports. The firm bought 46,989 shares of the company’s stock, valued at approximately $1,060,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Cetera Investment Advisers raised its holdings in Biodesix by 20.0% in the 1st quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock valued at $174,000 after acquiring an additional 2,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after purchasing an additional 2,235 shares in the last quarter. State Street Corp grew its holdings in shares of Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock worth $121,000 after purchasing an additional 2,400 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Biodesix during the 1st quarter worth $157,000. Finally, Thompson Davis & CO. Inc. bought a new position in shares of Biodesix in the first quarter worth $170,000. Institutional investors own 20.96% of the company’s stock.

Insiders Place Their Bets

In related news, Director Jack W. Schuler acquired 15,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average price of $24.47 per share, for a total transaction of $367,050.00. Following the completion of the acquisition, the director owned 555,810 shares of the company’s stock, valued at approximately $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired 42,600 shares of company stock valued at $1,033,062 over the last ninety days. Insiders own 23.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BDSX shares. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Canaccord Genuity Group boosted their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Roth Capital started coverage on Biodesix in a report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price target (up from $26.00) on shares of Biodesix in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.33.

Biodesix Stock Performance

Shares of BDSX stock opened at $23.25 on Tuesday. The company has a market cap of $245.29 million, a price-to-earnings ratio of -7.33 and a beta of 0.56. Biodesix, Inc. has a 52 week low of $5.26 and a 52 week high of $25.52. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. The firm has a 50 day moving average of $20.67 and a 200-day moving average of $16.32.

Biodesix (NASDAQ:BDSX) last released its earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.19. The company had revenue of $26.86 million for the quarter, compared to the consensus estimate of $26.03 million. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. On average, equities analysts forecast that Biodesix, Inc. will post -2.68 earnings per share for the current year.

Biodesix Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.